50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
S&P 500   3,655.04 (-1.03%)
DOW   29,260.81 (-1.11%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:EFTR

eFFECTOR Therapeutics - EFTR Stock Forecast, Price & News

$0.56
+0.00 (+0.37%)
(As of 09/26/2022 05:19 PM ET)
Add
Compare
Today's Range
$0.54
$0.58
50-Day Range
$0.50
$1.00
52-Week Range
$0.47
$17.99
Volume
151,310 shs
Average Volume
435,687 shs
Market Capitalization
$23.42 million
P/E Ratio
0.74
Dividend Yield
N/A
Price Target
$11.30

eFFECTOR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1,695.1% Upside
$10.30 Price Target
Short Interest
Healthy
1.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.76mentions of eFFECTOR Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$200,151 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

406th out of 1,069 stocks

Pharmaceutical Preparations Industry

183rd out of 533 stocks

EFTR stock logo

About eFFECTOR Therapeutics (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Stock News Headlines

eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 3%
eFFECTOR Therapeutics, Inc. (EFTR)
Analyst Ratings For eFFECTOR Therapeutics
See More Headlines
Receive EFTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

EFTR Company Calendar

Last Earnings
8/09/2022
Today
9/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EFTR
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.30
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,900.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$15.80 million
Pretax Margin
876.03%

Debt

Sales & Book Value

Annual Sales
$1.43 million
Cash Flow
$0.39 per share
Book Value
$0.43 per share

Miscellaneous

Free Float
34,282,000
Market Cap
$23.42 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Dr. Stephen T. Worland Ph.D. (Age 64)
    CEO, Pres & Director
    Comp: $753.39k
  • Mr. Michael Byrnes M.B.A. (Age 45)
    Chief Financial Officer
    Comp: $554.44k
  • Dr. Premal Patel M.D. (Age 51)
    Ph.D., Consultant
    Comp: $657.1k
  • Dr. Siegfried Reich Ph.D. (Age 62)
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Davide Ruggero Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Kevan M. Shokat Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Douglas Warner M.D.
    Chief Medical Officer













EFTR Stock - Frequently Asked Questions

Should I buy or sell eFFECTOR Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for eFFECTOR Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EFTR shares.
View EFTR analyst ratings
or view top-rated stocks.

What is eFFECTOR Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 12-month price objectives for eFFECTOR Therapeutics' shares. Their EFTR share price forecasts range from $5.00 to $20.00. On average, they predict the company's share price to reach $10.30 in the next year. This suggests a possible upside of 1,772.7% from the stock's current price.
View analysts price targets for EFTR
or view top-rated stocks among Wall Street analysts.

How have EFTR shares performed in 2022?

eFFECTOR Therapeutics' stock was trading at $8.28 at the beginning of 2022. Since then, EFTR stock has decreased by 93.4% and is now trading at $0.55.
View the best growth stocks for 2022 here
.

How were eFFECTOR Therapeutics' earnings last quarter?

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) released its earnings results on Tuesday, August, 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. The company had revenue of $2.01 million for the quarter.

What is eFFECTOR Therapeutics' stock symbol?

eFFECTOR Therapeutics trades on the NASDAQ under the ticker symbol "EFTR."

Who are eFFECTOR Therapeutics' major shareholders?

eFFECTOR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Parallel Advisors LLC (4.09%), Resolute Financial LLC (0.07%), Renaissance Technologies LLC (0.07%) and Callan Capital LLC (0.05%). Insiders that own company stock include Brian M Jr Gallagher, Christopher B Ehrlich, Jonathan D Root, Michael Byrnes, Presidio Management Group X Ll and Stephen T Worland.
View institutional ownership trends
.

How do I buy shares of eFFECTOR Therapeutics?

Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is eFFECTOR Therapeutics' stock price today?

One share of EFTR stock can currently be purchased for approximately $0.55.

How much money does eFFECTOR Therapeutics make?

eFFECTOR Therapeutics (NASDAQ:EFTR) has a market capitalization of $22.80 million and generates $1.43 million in revenue each year. The company earns $15.80 million in net income (profit) each year or $0.76 on an earnings per share basis.

How can I contact eFFECTOR Therapeutics?

eFFECTOR Therapeutics' mailing address is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. The official website for the company is www.locustwalkacquisitioncorp.com. The company can be reached via phone at 415-697-0763.

This page (NASDAQ:EFTR) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.